Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04647526
Title Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors POINT Biopharma
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Dexamethasone

Abiraterone + Prednisone

Enzalutamide

PNT2002

Age Groups: adult | senior
Covered Countries USA | FRA | CAN


No variant requirements are available.